We found for some dynamic clones, such as Case #3, subclone E (Clonal prevalence of ~0.46 in PreTx to ~0.99 in PostTx) and Case #29, subclone F (Clonal prevalence of ~0.53 in PreTx to ~0.99 in PostTx) they did not contain known HER2+ breast cancer driver gene mutations but potentially novel mutations which may be selected for under the pressure of therapy. Here, ERBB2 is linked to breast cancer.